🇺🇸 PTCT — PTC Therapeutics, Inc.

Salud Compra
← Volver

Precio actual

68,97 USD

Máx. histórico

89,55

118 días

Caída desde máximo

-22,98%

Rango 52 semanas

58,80 – 90,87

Variación hoy

+1,25%

Cierre anterior

68,12

Rango de hoy

66,87 – 70,11

Volumen hoy

1.266.047

Peor caída histórica

-94,60%

17/03/2015 → 03/11/2016

Recuperado en 3305 días

Volatilidad anualizada ⓘ

72,98%

Información
Nombre completo
PTC Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
991
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
100,47 USD (puede no estar actualizado)
Primera cotización
20/06/2013
Precio actualizado
hace 16 horas
Sobre la empresa

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
14/07/2017 19,16 19,85 18,95 19,39 +1,09% 4,70% 527.400
13/07/2017 18,73 19,41 17,99 19,18 +2,51% 7,58% 984.100
12/07/2017 19,99 19,99 18,34 18,71 -5,79% 8,25% 712.100
11/07/2017 18,84 19,95 18,84 19,86 +5,53% 5,89% 830.400
10/07/2017 19,25 19,56 18,60 18,82 -2,44% 4,99% 492.500
07/07/2017 19,37 19,72 19,08 19,29 -0,16% 3,30% 429.900
06/07/2017 19,41 19,70 19,08 19,32 -0,46% 3,22% 685.700
05/07/2017 18,77 19,70 18,68 19,41 +2,97% 5,43% 759.200
03/07/2017 18,47 19,35 18,34 18,85 +2,84% 5,47% 432.700
30/06/2017 18,36 18,50 18,09 18,33 -0,70% 2,26% 592.200
29/06/2017 18,37 18,64 18,05 18,46 +0,65% 3,21% 447.000
28/06/2017 17,94 18,86 17,73 18,34 +2,75% 6,30% 658.700
27/06/2017 18,31 18,69 17,53 17,85 -2,94% 6,34% 771.000
26/06/2017 18,43 18,67 18,03 18,39 +0,60% 3,47% 576.900
23/06/2017 17,96 18,46 17,59 18,28 +2,41% 4,84% 1.644.300
22/06/2017 17,49 18,20 17,32 17,85 +1,13% 5,03% 575.800
21/06/2017 17,07 17,74 17,00 17,65 +3,70% 4,34% 910.100
20/06/2017 17,21 17,56 16,82 17,02 -1,05% 4,30% 864.100
19/06/2017 17,10 17,63 16,79 17,20 +1,24% 4,91% 1.118.100
16/06/2017 16,60 17,00 16,45 16,99 +1,22% 3,31% 1.456.200
15/06/2017 16,74 17,00 16,34 16,79 -0,21% 3,94% 500.400
14/06/2017 16,85 17,05 16,22 16,82 +0,06% 4,93% 565.200
13/06/2017 16,56 17,19 16,30 16,81 +1,20% 5,34% 835.300
12/06/2017 16,37 16,82 15,73 16,61 +1,34% 6,66% 931.900
09/06/2017 16,41 17,00 16,00 16,39 +0,06% 6,12% 880.400
08/06/2017 15,56 16,45 15,18 16,38 +5,88% 8,16% 1.195.900
07/06/2017 14,41 15,90 14,41 15,47 +8,11% 10,34% 1.713.600
06/06/2017 14,08 14,86 13,89 14,31 +5,61% 6,89% 2.698.200
05/06/2017 13,17 13,60 12,99 13,55 +3,44% 4,67% 699.800
02/06/2017 12,66 13,18 12,51 13,10 +3,80% 5,29% 460.600